Khalid Zarug
Endocrinology, Diabetes & Metabolism · Evansville, INNPI 1629381447
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 452 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.
Across 452 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$795
- Dexcom, Inc.$635
- Amgen$617
- Abbott$609
- Medtronic$569
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,558100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $1,092 |
| Lilly USA, LLC | 44 | $795 |
| Dexcom, Inc. | 33 | $635 |
| Amgen | 34 | $617 |
| Abbott | 42 | $609 |
| Medtronic(2 entities) | 42 | $569 |
| Insulet Corporation | 31 | $548 |
| Boehringer Ingelheim | 24 | $342 |
| AbbVie | 19 | $296 |
| Corcept Therapeutics | 15 | $272 |
| Tandem Diabetes Care, Inc. | 12 | $195 |
| Recordati_rare_diseases_inc. | 9 | $187 |
| Mannkind Corporation | 10 | $165 |
| Antares Pharma, Inc. | 11 | $153 |
| AstraZeneca(2 entities) | 7 | $136 |
| Sanofi-aventis U.S. LLC | 8 | $122 |
| Novartis | 8 | $121 |
| BETA Bionics, Inc. | 3 | $94 |
| Bayer | 5 | $83 |
| Merck | 1 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Averitas Pharma Inc. | 2 | $55 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Radius Health, Inc. | 2 | $36 |
| Nevro Corp. | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $32 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
How this compares
$7,570 in reported general payments places this provider in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 328 | $509,375 |
| JardianceEmpagliflozin | 270 | $298,463 |
| MounjaroTirzepatide | 113 | $149,925 |
| TrulicityDulaglutide | 74 | $115,372 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $110,673 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 57 | $84,472 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $59,014 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $49,308 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 234 | $47,533 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $42,507 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $40,580 |
| Humalog Kwikpen U-100Insulin Lispro | 84 | $38,381 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $37,721 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 69 | $36,244 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $33,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba | $1,092 | $543,070352 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $342 | $353,419314 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $795 | $268,871200 claims |
| AstraZenecaFarxiga | $136 | $25,44629 claims |
| MerckJanumet Xr | $63 | $14,22811 claims |
| Johnson & JohnsonInvokana | $13 | $12,97017 claims |
| Antares Pharma, Inc.Xyosted | $153 | $11,67313 claims |
| AbbVieSynthroid | $296 | $11,627144 claims |
| Clarus Therapeutics Inc.Jatenzo | $14 | $9,21513 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $6,460782 claims |
| Sanofi-aventis U.S. LLCLantus | $122 | $4,87029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Evansville
- Mary TadrosEvansville$6K
- Yousef AltowairebEvansville$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.